Flagship Pioneering

Invus

Partners Investment

T. Rowe Price

UPMC Enterprises

Altitude Life Science Ventures

CJ Investment

Alexandria Venture Investments

Kyowa Kirin

Ring Therapeutics

#ICYMI we presented our first NHP data on our #Anellovectors and #AnelloBricks platform at #ESGCT2023. We’re dedicated to revolutionizing the gene therapy and nucleic acid medicine space. Catch up on the data presented here: https://brnw.ch/21wEiKw

Last week, our team took a break from the lab bench and headed out on a city-wide scavenger hunt for a chance to explore our new neighborhood in East Cambridge. Check out these selfies and sites from the competition & congrats to our winners Ashley Tang , Daniel Elliott MBA, SHRM-SCP, Gowtham Akash Jayakumar, Jake Matte, Kavya Atluri, Patricio Jeraldo, and Laurindo Fonseca for taking home the prize during this exciting team bonding activity!

We’ve landed in Brussels for #ESGCT2023! Come stop by and check out our posters showcasing the first NHP transduction data for our #Anellovectors and #AnelloBricks platform. If you can't make it, check out poster details here: https://brnw.ch/21wDRy3

This week, we are presenting new data at the 30th Annual European Society of Gene and Cell Therapy (ESGCT) Conference! Come check out our posters where Geoffrey Parsons will highlight the first NHP transduction data for #Anellovectors and our unique manufacturing approach with #AnelloBricks. Read more about our data here:  https://lnkd.in/eTzKS8td #ESGCT2023

Our #CEO Dr. Tuyen Ong was recently featured in a Genetic Engineering & Biotechnology News article discussing how anelloviruses can address current challenges in genetic medicine and the potential of AnelloVectors from our #Anellogy platform. Read more: https://brnw.ch/21wDorc

At Ring, we're translating the unique biology of commensal anelloviruses into AnelloVectors with our #Anellogy platform.  Learn more about how we're transforming these commensal viruses into life-saving therapies: https://brnw.ch/21wDcIe

We are incredibly proud to be part of Flagship Pioneering as we take bold leaps to tackle challenges in genetic medicine. At Ring, we’re committed to pushing the boundaries of what is possible with our #Anellogy platform. #FlagshipFounded

Today we announced two late-breaking presentations at the 30th Annual European Society of Gene and Cell Therapy (ESGCT) conference in Brussels! Come check out new data from our #Anellogy platform and learn about our unique approach to #genetherapy manufacturing. Read more about our presentation details here: https://brnw.ch/21wCWC7 #ESGCT2023

This summer, we transitioned to a new space to support the growth of our team! This space was meticulously designed to inspire brilliance & collaboration so we can continue pushing boundaries in genetic medicine with our #Anellogy platform. Join us: https://brnw.ch/21wCQrd

#TBT Our CEO Dr. Tuyen Ong chatted with Jonathan Grinstein from Genetic Engineering & Biotechnology News about addressing safety in gene editing and the importance of derisking novel approaches. Click here to read more:  https://fal.cn/3AqY4

Google Maps

Ninja Forms

Chief Executive Officer

Tuyen Ong

SVP of Finance

Dean Profis

Senior Vice President, Technical Operations

John Huynh

Human Resources

Megan Daley Woods

Finance and Administration

Alice Kuo

Associate Director Upstream Process Development

Amy Correia

Marketing and Product

Anne Joseph

Engineering

Ashley Mackey

Director, Business Development and External Alliances

Brian Luque

Director, in Vitro Biology

Bryan Vought

B. Lynne Parshall

Torben Straight Nissen

Konstantin Konstantinov

Chief Technology Officer

David Epstein

Independent Director

Yong Chang

Chief Scientific Officer

Avak Kahvejian

Chairman & Founder

Kevin B. Johnson

Chief Regulatory Officer

Erica Weinstein

Co-Founder and Advisor

Northeastern US Companies With Less Than $50M in Revenue (Top 10K)

Greater Boston Area Startups with Female Founders

Northeastern US Late Stage Companies With More Than 10 Employees

Greater Boston Area Biotechnology Companies

Ring Therapeutics is a multi-product platform company focused on discovering and developing Anellovector therapeutics to unlock the full potential of gene therapy. Founded by Flagship Pioneering, Ring is pioneering the first redosable and targetable gene therapy platform by harnessing the biology of the human commensal virome. The company is expanding the applications of gene therapy beyond gene replacement, enabling a much wider array of modalities and mechanisms to treat previously inaccessible diseases.

Series C - Ring Therapeutics

Series B - Ring Therapeutics

Venture Round - Ring Therapeutics

Computer and Software Services and Scientific Services

Cambridge

Massachusetts

United States

North America

Ring Therapeutics expands Singapore footprint with new deals

Ring Therapeutics Announces New Strategic Partnerships with A*STAR and SERI to Establish Gene Therapy R&D Efforts in Singapore, a Growing Global Biotech Hub

Madeline Schanen’s Post

ASGCT: Ring's 'new class of viral vector' is re-dosable in primates, overcoming key challenge of AAVs

In major step toward the clinic, Ring's human viral vector delivers gene therapy to eyes of mice

A discovery engine for identifying and characterizing anellovirus diversity to design genetic medicines.

Technology for characterizing new anelloviruses in terms of tissue tropism, redosability, potency, and immunogenicity.

A computational pipeline that combines genomic information to design AnelloVectors targeting specific tissues without unwanted immunogenicity.

Engineered viral particles for delivering nucleic acids to cells in various tissue types without integrating onto chromosomal DNA.

Engineered viral particles with payloads conjugated to their surface, designed for immune evasion and therapeutic value across various indications.

A manufacturing platform for producing therapies efficiently at scale, supporting clinical development and commercial production of AnelloVector drug products.

India

Asia

Ring Therapeutics is a biotechnology research company based in Cambridge, Massachusetts. Founded in 2017 by Flagship Pioneering, Ring is powering a new era of gene therapy by harnessing the unique biology of commensal anelloviruses. Their research aims to develop anellovirus-based therapies with tissue and cellular tropism, payload versatility, potency, and redosability.

news impact assignment basic	general
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 25, 2024 9:09 AM	e77c2b07
crunchbase profile	general	Nov 25, 2024 11:36 AM	7367df4d
li profile	general	Dec 1, 2023 12:18 AM	0d67513c
translate crunchbase fundingrounds	general	Nov 25, 2024 3:03 PM	e66963e0
peers	general
news basic	general
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:RINGTX

Ring Therapeutics